Translational-Research
Translational-Research funding pages collect matching grants, scholarships, benefits, fellowships, and other programs from the FindMyMoney.App directory. Use this page to compare current opportunities, then verify deadlines and eligibility on the official source before applying.
NIH Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)
This NIH PAR-26-116 cooperative agreement supports translational research led by extramural investigators that uses NIH Clinical Center infrastructure through a planned collaboration with NIH intramural investigators.
NIH Quantum Sensing Technology Challenge
A two-stage NIH prize competition led by NCATS to accelerate biomedical use cases for quantum-enabled sensing technologies through team-based development, with milestone-based cash awards through 2026 and 2027.
PAR-27-072: Bioengineering Research Grants (R01) for Translational Biomedical Engineering
NIH Bioengineering Research Grants support R01 applications that integrate engineering, quantitative, and physical science approaches to create or adapt technologies and methods that can be translated into biomedical solutions, with recurring deadlines across 2026 and 2027 and open intake.
RFA-DA-26-034: Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on the Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic Opioids
NIH Trans-NIH RFA supports basic and applied research on acute exposure effects and delayed effects of ultra-potent synthetic opioids, with recurring R01 due dates in 2026 and 2027.
RFA-DE-27-002: Accelerating Product Excellence in Innovation and for Clinical Adoption (APEx) (U24 Clinical Trial Not Allowed)
NIH Notice of Funding Opportunity to build a U24 Tissue Engineering and Regenerative Medicine Resource Center with an initial cohort of Interdisciplinary Translational Projects focused on pre-clinical de-risking and FDA-oriented readiness.
RFA-HL-26-017: NIH Catalyze Product Definition for Small Molecules and Biologics (R61/R33)
NIH's RFA-HL-26-017 supports early-stage translational projects that generate and validate therapeutic candidates for HLBS diseases through a phased R61/R33 development pathway.
RFA-HL-26-019: Catalyze Product Definition - Medical Device Prototype Design/Testing, Diagnostics, and Assay Development (R61/R33)
NIH NHLBI Catalyze Product Definition NOFO for phased R61/R33 support of early-stage device, diagnostic, and assay development (clinical trials not allowed), with ongoing application rounds in 2026 and 2027.